FDA approves Novartis Scemblix® (asciminib), with novel

  Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate...

Related Keywords

Philadelphia , Pennsylvania , United States , Michaelj Mauro , Susanne Schaffert , Lee Greenberger , Approval Program , Leukemia Lymphoma Society , Drug Administration , Novartis , Accelerated Approval Program , Chief Scientific Officer , Myeloproliferative Neoplasms Program Leader , Memorial Sloan Kettering Cancer Center , Prescribing Information , Novartis Commitment , Swiss Stock Exchange Novn , Novartis Pharma Ag , Media Release , Reimagine Medicine , Ncology , Dancer ,